The role of extracellular matrix metalloproteinases and their inhibitors in allergic diseases

Postepy Dermatologii i Alergologii

Volumn 29, Issue 5, 2012, Pages 384-389

  Kuzḿiński, Andrzej ^a   Przybyszewski, Michał ^a   Graczyk, Magorzata ^a   Bartuzi, Zbigniew ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Extracellular matrix; Metalloproteinase inhibitors; Metalloproteinases

Indexed keywords

CD147 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 6; COLLAGENASE 3; EPIDERMAL GROWTH FACTOR; GELATINASE; GELATINASE A; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PARATHYROID HORMONE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; STEROID HORMONE; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; BASEMENT MEMBRANE; CELL MIGRATION; CHRONIC URTICARIA; COLLAGEN DEGRADATION; DISEASE EXACERBATION; DISEASE SEVERITY; EFFECTOR CELL; ENZYME REGULATION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INTERCELLULAR SPACE; REVIEW; SKIN ALLERGY;

EID: 84869205692     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: 10.5114/pdia.2012.31493     Document Type: Review

References (42)

1. Lipka D, Boratyński J. Metalloproteinases. Structure and function. Post Hig Med Dów 2008; 62: 328-36.
2. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39. (Pubitemid 36542523)
3. Hrabec E, Naduk J, Strȩk M, Hrabec Z. Collagenases type IV [MMP-2 and MMP-9], and their substrates-extracellular matrix proteins, hormones, cytokines, chemokines and their receptors. Post Biochem 2007; 53: 37-45.
4. Wong T, Sethi C, Daniels J, et al. Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv Ophthalmol 2002; 47: 239-56. (Pubitemid 34575357)
5. Żebrowski M, Kierus-Gudaj A, Żebrowska A. The role of metalloproteinases in etiology of coronary heart disease. Forum Kardiologów 2003; 8: 53-7.
6. Oelmann E, Herbst H, Zuhlsdorf M, et al. Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells. Blood 2002; 99: 258-67.
7. Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 2005; 87: 249-63. (Pubitemid 40387604)
8. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-60. (Pubitemid 27230597)
9. Ala-aho R, Kahari V. Collagenases in cancer. Biochimie 2005; 87: 273-86. (Pubitemid 40387606)
10. Murphy G, Houbrechts A, Cockett M, et al. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991; 30: 8097-102.
11. Kowalski M, Walczak A, Majsterek I. Matrix metalloproteinases (MMPs): modern molecular markers of open-angle glaucoma diagnosis and therapy. Postȩpy Hig Med Dośw 2008; 62: 582-92.
12. Birkedal H. Role of cytokines and inflammatory mediators in tissue destruction. J Periodontal Res 1993; 28: 500-10.
13. Ruhul Amin A, Senga T, Oo M, et al. Secretion ofmatrix metalloproteinase-9 by the proinflammatory cytokine, IL-1beta: a role for the dual signalling pathways. Akt Erk Genes Cells 2003; 8: 515-23. (Pubitemid 36748455)
14. Xu J, Rodriguez D, Petitclerc E, et al. Proteolitic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001; 154: 1069-79. (Pubitemid 34286185)
15. Nip L. Inhibition of epithelial cell matrix metalloproteinases by tetracyclines. J Periodontal Res 1993; 28: 379-85. (Pubitemid 23282035)
16. Larry M, Corcoran W. Regulation of monocyte/macrophage metalloproteinase production by cytokines. J Periodontol 1993; 64: 467-73.
17. Łukaszewicz M, Mroczko B, Szmitkowski M. The role of metalloproteinases and their inhibitors in pancreatic cancer. Postep Hig Med Dośw 2008; 62: 141-7.
18. Stankiewicz-Choroszucha BL, Wawrzyniak ZM, Lipiec A, et al. Consequences of smoke inhalation in the 'Epidemiology of Allergic Diseases in Poland' project (ECAP). Ann Agric Environ Med 2011; 18: 420-8.
19. Fal A, Rabski M. The role of neutrophil in asthma - new therapeutic perspectives. Alergia 2006; 2: 37-42.
20. Bellegulic C, Corbel M, Germain N, et al. Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients. Clin Exp Allergy 2002; 32: 217-23. (Pubitemid 34429599)
21. Oshita Y, Koga T, Kamimura T, et al. Increased circulating 92 kDa matrix metaloproteinase (MMP-9) in exacerbation in asthma. Thorax 2003; 58: 757-60. (Pubitemid 37094050)
22. Ko F, Diba C, Roth M, et al. A comparison of airway and serum matrix metalloproteinase-9 activity among normal subjects, asthmatic patients, and patients with asthmatic mucus hypersecretion. Chest 2005; 127: 1919-27.
23. Mautino G, Capony F, Bousquet J, et al. Balance in asthma between matrix metalloproteinases and their inhibitors. J Allergy Clin Immunol 1999; 104: 530-3. (Pubitemid 29451639)
24. Matsumoto H, Niimi A, Takemura M, et al. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax 2005; 60: 277-81. (Pubitemid 40522362)
25. Takafuji S, Ishida A, Miyakuni Y, et al. Matrix metalloproteinase-9 release from human leukocytes. J Investig Allergol Clin Immunol 2003; 13: 50-5. (Pubitemid 36781523)
26. Van den Steen P, Proost P, Wuyts A, et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96: 2673-81.
27. Harper J, Godwin H, Green A, et al. A study of matrix metalloproteinase expression and activity in atopic dermatitis using a novel skin wash sampling assay for functional biomarker analysis. Br J Dermatol 2010; 162: 397-403.
28. Devillers A, van Toorenenbergen A, Heerenbrink G, et al. Elevated levels of plasma matrix metalloproteinase-9 in patients with atopic dermatitis: a pilot study. Clin Exp Dermatol 2007; 32: 311-3. (Pubitemid 46495803)
29. Katoh N, Hirano S, Suehiro M, et al. Increased levels of serum tissue inhibitor of metalloproteinase-1 but not metalloproteinase-3 in atopic dermatitis. Clin Exp Immunol 2002; 127: 283-8. (Pubitemid 34233934)
30. Kessel A, Bishara R, Amital A, et al. Increased plasma levels of matrix metalloproteinase-9 are associated with the severity of chronic urticaria. Clin Exp Allergy 2005; 35: 221-5. (Pubitemid 40353786)
31. Tedeschi A, Asero R, Lorini M, et al. Plasma levels of matrix metalloproteinase-9 in chronic utricaria patient correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy 2010; 40: 875-81.
32. th May 2007, P1356.
33. Altrichter S, Boodstein N, Maurer M. Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic utricaria patients? Allergy 2009; 64: 652-6.
34. Antiga E, Volpi W, Del Bianco E, et al. Plasma levels of metalloproteinaze-9 are elevated in patients with chronic autoimmune utricaria. Br J Dermatol 2009; 161: 712-4.
35. Rapiejko P. Early and late phase of allergic reaction of nasal mucosa. Alergoprofil 2007; 3: 7-13.
36. Bugdayci G, Kaymakci M, Bukan N. Matrix metalloproteinase-9 (MMP-9) in allergic nasal polyps. Acta Histochemica 2010; 112: 92-5.
37. Leonardi A, Brun P, Di Stefano A, et al. Matrix metalloproteinases in vernal keratoconjunctivitis, nasal polyps and allergic asthma. Clin Exp Allergy 2007; 37: 872-9. (Pubitemid 47074563)
38. Wang M, Qin J, Mudgett T. MMP deficiencies affect contact hypersensitivity: stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response. Immunology 1999; 96: 6885-9. (Pubitemid 29274979)
39. Lebre M, Kalinski P, Das P, et al. Inhibition of contact sensitizer-induced migration of human Langerhans cells by matrix metalloproteinase inhibitors. Arch Dermatol Res 1999; 291: 447-52. (Pubitemid 29396835)
40. Gianelli G, Foti C, Marinosci F, et al. Gelatinase expression at positive patch test reactions. Contact Dermatitis 2002; 46: 280-5. (Pubitemid 34753730)
41. Reduta T, Laudańska H, Laudanski P. Tissue inhibitors of MMP-1 levels are increased in serum of patients with allergic contact dermatitis. Contact Dermatitis 2007; 57: 100-4. (Pubitemid 47052292)
42. Bruce C, Thomas P. The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyperreactivity. Toxicol Appl Pharmacol 2005; 205: 126-32. (Pubitemid 40704647)